Clinical trial · Observational
Biomarkers in Tissue Samples From Older Women With Breast Cancer
PIK3CA Mutation Status as a Biomarker in Elderly Women With Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study closed prematurely.
Summary
Brief summary (as posted)
This research trial studies phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutation analysis in tissue samples from older patients with stage I breast cancer. Studying samples of tissue from patients with stage I breast cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Breast cancer-free interval for patients with PIK3CA-mutated tumors
- timeFrame
- baseline
- measure
- Tumor size
- timeFrame
- baseline
- measure
- Estrogen receptor status
- timeFrame
- baseline
- measure
- Lymph node status
- timeFrame
- baseline
- measure
- Treatment group associated with PIK3CA expression
- timeFrame
- baseline
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 70 Years
Show eligibility criteria text
* Participants with stage I breast cancer (T1N0M0) and estrogen-receptor status positive or unknown * Patients underwent lumpectomy with negative margins and were clinically node-negative
References
Publications (0)
Data not yet available